DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Losmapimod is an investigational drug.
There have been 11 clinical trials for Losmapimod. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Acute Coronary Syndrome, Pulmonary Disease, Chronic Obstructive, and Muscular Dystrophy, Facioscapulohumeral. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and The TIMI Study Group.
There are nine US patents protecting this investigational drug and eighty-seven international patents.
Recent Clinical Trials for Losmapimod
|Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)||Fulcrum Therapeutics||Phase 2|
|Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)||Fulcrum Therapeutics||Phase 2|
|Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1||Fulcrum Therapeutics||Phase 2|
Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Losmapimod||Start Trial||P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD||Fulcrum Therapeutics, Inc. (Cambridge, MA)||Start Trial|
|Losmapimod||Start Trial||Nicotinamide derivatives useful as p38 inhibitors.||SmithKline Beecham Corporation (Philadelphia, PA)||Start Trial|
|Losmapimod||Start Trial||Nicotinamide derivatives useful as p38 inhibitors||SmithKline Beecham Corporation (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|